Ekso Bionics (EKSO) Shares Up 7.4%
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) shot up 7.4% on Friday . The stock traded as high as $2.05 and last traded at $2.02. 1,361,300 shares were traded during mid-day trading, an increase of 30% from the average session volume of 1,047,263 shares. The stock had previously closed at $1.88.
Several research firms have weighed in on EKSO. ValuEngine upgraded shares of Ekso Bionics from a “strong sell” rating to a “sell” rating in a research report on Friday, November 17th. Zacks Investment Research upgraded shares of Ekso Bionics from a “sell” rating to a “hold” rating in a research report on Tuesday.
The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 5.73. The stock has a market cap of $121.01, a PE ratio of -2.16 and a beta of 2.01.
Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.40 million. equities research analysts predict that Ekso Bionics Holdings, Inc. will post -0.81 earnings per share for the current year.
In related news, insider Russ Angold sold 50,000 shares of Ekso Bionics stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total transaction of $175,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.32% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in EKSO. Intellectus Partners LLC lifted its stake in Ekso Bionics by 5.3% in the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares in the last quarter. Carl Domino Inc lifted its stake in Ekso Bionics by 125.2% in the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock valued at $224,000 after buying an additional 102,734 shares in the last quarter. Vanguard Group Inc. lifted its stake in Ekso Bionics by 32.9% in the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares in the last quarter. Finally, National Planning Corp lifted its stake in Ekso Bionics by 122.2% in the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock valued at $620,000 after buying an additional 286,492 shares in the last quarter. 6.22% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Ekso Bionics (EKSO) Shares Up 7.4%” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/ekso-bionics-ekso-shares-up-7-4/1804726.html.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with Analyst Ratings Network's FREE daily email newsletter.